Eris Lifesciences Q1 FY27 results: Revenue up 13 percent, PAT at Rs 143 Cr

EBITDA margin compressionExceptional itemResults View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.5%Reaction day

₹1390.00

prior close

₹1409.20

announcement price

In-mkt

timing

Nifty Smallcap 250market+1.3%+1.2% vs market

Pharmaceuticals peers, median of 160sector+0.8%+1.8% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty Smallcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.7

15m

+0.3

30m

+0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.5+1.3+1.2+0.8+1.8

Next day

-0.7+0.6-1.3+0.0-0.7

-2.2+1.0-3.2+0.1-2.2

-0.1+2.4-2.5+0.6-0.8

-0.9+2.6-3.4+1.0-1.9

-1.1+3.3-4.4+0.6-1.7

-0.3+3.5-3.8+1.6-1.9

15d

-2.9+2.8-5.6+0.5-3.4

-6.1+3.6-9.7+2.1-8.2

-12.2+0.0-12.2+4.2-16.4

-16.1-3.6-12.5-1.9-14.2

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris Lifesciences board approved Q1 FY27 results for quarter ended June 30, 2026. Revenue from operations grew to Rs 873.25 Cr from Rs 773 Cr YoY, around 13 percent. Net profit rose to Rs 143.32 Cr from Rs 125.10 Cr. EPS stood at Rs 10.28. Operating margin slipped to 25.94 percent from 27.02 percent. Auditor issued an unmodified opinion. Board also re-appointed Kiran J Mehta and Co as Cost Auditors for FY 2026-27.

Likely market impact

Solid top-line and profit growth with slight margin pressure. Clean audit opinion and stable cost auditor are reassuring for shareholders.